AbbVie Inc. (ABBV)
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends to move in a positive direction regardless of what's happening to the overall economy.
Top 4 Immunology Stocks Poised For Growth In 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.
Income & Growth: 3 Of The Best Dividend Stocks For Any Market
Inflation continues to erode purchasing power, and recent volatility highlights the uncertainty in inflation trends. Despite this, long-term investors can still find opportunities. In an unpredictable environment, focusing on companies with resilient business models can provide stability. Coca-Cola, AbbVie, and TC Energy stand out in this regard. These stocks offer defensive growth, attractive dividends, and strong fundamentals. They're well-positioned to navigate inflation while providing consistent income and long-term returns.
Why the Market Dipped But AbbVie (ABBV) Gained Today
In the most recent trading session, AbbVie (ABBV) closed at $173.70, indicating a +1.37% shift from the previous trading day.
AbbVie Inc. (ABBV) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV ) J.P. Morgan 43rd Annual Healthcare Conference January 15, 2025 11:15 AM ET Company Participants Rob Michael - Chief Executive Officer Scott Reents - Executive Vice President, Chief Financial Officer Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer Conference Call Participants Chris Schott - J.P.
AbbVie to 'commit less capital' towards psychiatric drugs, CEO says
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday.
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 Brilliant Dividend Growth Stocks That Can Supercharge Your Portfolio
Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their dividends tend to possess durable competitive advantages, robust cash flows, and shareholder-friendly management teams.
3 High-Yielding Dividend Stocks That Could Be Ideal Investments for Retirees
If you're a retiree looking for dependable and reliable dividend income, there are many quality stocks out there that can be suitable options for your portfolio. The stocks I've listed below pay above-average yields, grow their dividends on a regular basis, and aren't volatile investments.
AbbVie Has Immense Cash Flow Potential
AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with adjusted diluted EPS at $3/share and nearly $15 billion in revenue, up 4%. The updated guidance includes $1.6 billion in acquisition expenditures, impacting adjusted earnings, and recent acquisitions to strengthen immunology and neuroscience pipelines.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
